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Cystic fibrosis is the most common life-shortening genetic disease affecting Caucasians,
clinically manifested by fat malabsorption, poor growth and nutrition, and recurrent
sinopulmonary infections. Newborn screening programs for cystic fibrosis are now
implemented throughout the United States and in many nations worldwide. Early
diagnosis and interventions have led to improved clinical outcomes for people with cystic
fibrosis. Newer cystic fibrosis transmembrane conductance regulator potentiators and
correctors with mutation-specific effects have increasingly been used in children, and
these agents are revolutionizing care. Indeed, it is possible that highly effective modulator
therapy used early in life could profoundly affect the trajectory of cystic fibrosis lung
disease, and primary prevention may be achievable.
Keywords: cystic fibrosis, cystic fibrosis transmembrane conductance regulator, corrector, potentiator,
immunoreactive trypsin(ogen), sweat chloride test, newborn screening
INTRODUCTION
Newborn screening (NBS) programs were first established almost 60 years ago in the United States
after the seminal discovery that phenylalanine could be detected from a dried blood spot,
ultimately leading to early diagnosis of phenylketonuria and avoidance of the severe neurocognitive
complications characteristic of this inherited metabolic disorder (1). Other screening programs
emerged, generally adhering to basic principles outlined in a report commissioned by the World
Health Organization (2), and the number of diseases tested has grown in the last several decades.
While there is variability between programs, some states and countries screen for as many as 50
treatable metabolic conditions, endocrinopathies, hemoglobinopathies, and genetic diseases, like
cystic fibrosis (CF).
Occurring in roughly 1 in 3,000 live births in the United States, based on epidemiological and
neonatal screening data, CF is the most common, life-shortening inherited disease of Caucasians
(3). CF is caused by defective CF transmembrane conductance regulator (CFTR), a cAMP-regulated
anion transporter expressed on the surface of various epithelia. Functionally linked to the epithelial
sodium channel and other apical channels, CFTR abnormalities lead to reduced epithelial chloride
conductance and sodium absorption, resulting in dehydration of the periciliary fluid layer and
mucus on the airway surface that impairs mucociliary clearance (4, 5). Innate defenses are also
compromised by altered bicarbonate secretion in the CF airway (6, 7). Together, these changes
lead to progressive airway obstruction, allowing bacterial infection to become established and
provoking a persistent neutrophilic inflammatory response that results in the gradual destruction
of the airways and ultimately respiratory failure.
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Before implementation of NBS for CF, children were
typically diagnosed after developing symptoms consistent with
fat malabsorption, often leading to nutritional failure. Some
were identified shortly after birth when they presented with
meconium ileus, which occurs in roughly 15% of children with
CF (8, 9). Recurrent respiratory infections, often misdiagnosed
as asthma or bronchiolitis, would occur during infancy, but are
more common in older children. Indeed, children with milder,
pancreatic sufficient phenotypes are often recognized later as
their respiratory symptoms become more prevalent.
Adoption of NBS in many nations has led to earlier diagnosis
and treatment, and the life expectancy of a child born with
CF in many parts of the world has steadily improved (10, 11).
In addition, newer, small molecule therapeutics have begun to
dramatically change the disease (12, 13). In this article, we
will review NBS for CF and describe existing and emerging
therapies that have impacted the progressive respiratory decline
of people with CF and how they may avert lung disease and other
complications even before they begin.
NBS FOR CF
Early attempts to screen neonates for CF over 40 years ago
relied on measuring albumin content in dried meconium
(14), which had a high false-positive rate. However, it was
discovered that young infants with CF had elevated, circulating
levels of pancreatic enzymes and proenzymes, even children
with pancreatic sufficient forms of the disease. In particular,
trypsinogen, a pancreatic enzyme precursor released from the
inflamed exocrine pancreas caused by inspissated secretions
and destruction of acinar cells, can be detected in the blood
of neonates with CF. Indeed, over 40 years ago, Crossley and
colleagues showed that the serum immunoreactive trypsinogen
(IRT) could be measured in blood spots dried on the Guthrie
cards (15), and the ability to measure this analyte was paramount
for development of a broad, population-based newborn program.
In the United States, methods for NBS differ between states
and countries, but all invariably use some form of the IRT
measurements as part of the screening process. It is important
to note that IRT concentrations can be elevated in the absence
of CF, particularly in neonates who are premature, have low
Apgar scores, or experience perinatal stress. It was recognized
that a single-tier approach had a lower sensitivity, so in the
United States, most states have adopted two-tier protocols that
involve serial IRT measurements repeated 1 to 2 weeks apart if
the initial value is elevated, or IRT followed by genetic testing
for specific CFTR mutations if abnormal. Some states have
adopted a third-tier, using a protocol that involves repeated
measurements of IRT levels, with DNA analysis performed if
both concentrations are above the designated threshold (16, 17).
Uniquely, California, a state that has a racially diverse population,
has incorporated CFTR sequencing in their screen to identify CF
Abbreviations: cAMP, cyclic adenosine monophosphate; CF, cystic fibrosis;
CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced
expiratory volume in one second; IRT, immunoreactive trypsinogen; NBS,
newborn screening.
in neonates with high IRT concentrations and only one mutation
in their genetic panel (18).
The threshold defining an elevated IRT level varies between
states. While some states will apply an absolute concentration to
prompt further testing, others use percentile cutoffs that improve
specificity. Serial IRT approaches without genetic analysis has
benefits, allowing for identification of individuals with less
common CFTR mutations in certain populations (19), but
delaying time to a positive screen because the second specimen
is obtained later. Genetic panels used in NBS are variable, and
the number of CFTR mutations analyzed may differ from state-
to-state. Genetic testing has the advantage of identifying people
who are heterozygous for CFTR mutations, but also more likely
to identify patients with mutations but normal or equivocal sweat
chloride levels, referred to as CFTR-related metabolic syndrome
or, in Europe, CF screen-positive, inconclusive diagnosis.
ADOPTION AND EVOLUTION OF CF NBS
In the United States, NBS for CF was slowly accepted, given
the relative absence of data showing benefits of early diagnosis.
Indeed, even the Cystic Fibrosis Foundation was hesitant to
make a recommendation regarding NBS, stating the benefits
of presymptomatic and early treatment were controversial (20).
Nevertheless, screening programs were established in North
America. In 1982, Colorado became the first state to implement
NBS for CF, followed shortly thereafter by Wisconsin. Initially
developed as part of a decade-long randomized controlled trial
(21), NBS was added to the Wisconsin state-wide program
in 1994 (22). A workshop held by the Centers for Disease
Control and Prevention and Cystic Fibrosis Foundation in 2003
evaluated diagnostic testing and decision-making and provided
recommendations for best practices for screening for CF (23). At
the time of its publication, only eight states had implemented an
NBS program, but within 7 years, all 50 states and Washington,
DC, had screening programs for CF, with Texas being the last
state to implement screening.
Similar to the US experience, there is considerable variability
in screening programs among nations. Certainly, disease
prevalence plays an influential role in the need for screening
and early diagnosis (24, 25). Worldwide, Australia and New
Zealand were pioneers, establishing NBS programs in 1981 (26).
During the past two decades, the number of programs has rapidly
increased in Europe (25, 27), with more than 20 European
countries performing NBS at some level. Indeed, alternative
screening approaches have been adopted in some countries.
For instance, a four-tier screening algorithm was created in the
Netherlands that involves measurement of IRT and pancreatitis-
associated protein levels from the same dried blood spot (28),
CFTR mutation panel, and, if indicated, extended genomic
analysis. The Dutch experience highlights the complexity of such
programs, and a reminder NBS is exactly that, a screening tool
and not a diagnostic test.
Often overlooked, successful NBS depends on the accuracy
of diagnostic testing. The diagnosis of CF is based on elevated
sweat chloride concentrations (29). Any clinical concerns
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for CF, regardless of the screening result, are an indication
for sweat chloride measurement. While other approaches
are available, the only reliable, validated diagnostic test for
measuring sweat chloride concentration is the quantitative
pilocarpine iontophoresis test, performed according to Clinical
and Laboratory Standards Institute guidelines (30).
BENEFITS OF NBS FOR CF
NBS, regardless of disease, is successful only if early identification
is feasible using simple, cost-effective means and can lead to
improved clinical outcomes. For decades, the diagnosis of CF
required clinical suspicion. Before screening, the median age
of diagnosis was 6 months in the United States, and nearly
70% of affected children were identified by their first birthday
(31). Malnutrition occurs early in life (32), and pulmonary
involvement can begin early in infancy, despite the child
appearing asymptomatic (33, 34). With widespread adoption of
NBS in the United States, the age at diagnosis has shifted to <1
month, often before the child is symptomatic.
There was early evidence from the Netherlands almost 5
decades ago that screening in the neonatal period was associated
with a survival benefit (35). While CF was added relatively late to
US programs, there was growing evidence that delayed diagnosis
would have serious implications for affected people. Because
of low mortality rates in children, it is difficult to establish
survival differences between screened and unscreened children
with CF. Using data from the US Cystic Fibrosis Foundation
Patient Registry of more than 27,000 patients, children identified
by screening within a month of age and treated early had better
survival compared to counterparts diagnosed symptomatically
(36), supported by several subsequent studies (37–39).
The best evidence clearly showing benefits of NBS is its effect
on early nutrition and growth. Before screening, children with
CF were often diagnosed after becoming severely malnourished
with vitamin deficiencies. These children frequently failed to
achieve their growth potential and had evidence of impaired
development of cognitive function, likely related to malnutrition.
Investigators in Wisconsin unsurprisingly found that the
diagnosis of CF was confirmed by a positive sweat test at
a much younger age in a screened cohort as compared to
controls. Moreover, children with CF identified by screening
had significantly better height, weight, and head circumference
percentiles, and these differences persisted throughout infancy
and early childhood, especially the children who had pancreatic
insufficiency and homozygous for the Phe508del mutation (40).
Recently, a multicenter, longitudinal, observational cohort study
examined the nutritional health of 231 American children with
CF identified by NBS over a 3-year period and found significant
improvement in nutritional status, with normalization of weight
in the first year of life (41).
Malnourished children with CF have increased risk of chronic
lung disease. A large study of 931 children with CF examining
the effect of early nutrition on the development of lung disease
highlighted the importance of earlier intervention. Children with
better nutritional indices at 3 years of age had higher lung
function measures at the age of 6 years (42). Thus, early diagnosis
in order to optimize the nutritional status by starting enzymes
at diagnosis and adding nutritional supplements as indicated can
lead to improved pulmonary health.
There have been several studies that show children diagnosed
with CF following NBS have fewer complications than those
who were symptomatic at the time of diagnosis. Australian
investigators compared the outcomes of children with CF
identified early from NBS or diagnosed late. Unscreened patients
had reduced height, lower pulmonary function measures, and
increased rates of infection and colonization with Pseudomonas
aeruginosa (43). Respiratory benefits persisted into adolescence
(44, 45). Others have similarly shown benefits in the US and
UK populations, with reduced P. aeruginosa infections, reduced
treatment burden, and fewer hospitalizations (46–48). These
findings emphasize not only the importance of early diagnosis
and detection, but also the need for continued improvement of
screening protocols with genetic advances.
In addition to the clinical benefits from early identification,
screening programs for CF have economic benefits, with several
studies revealing its cost-effectiveness (49, 50). Additionally,
investigators have reported that the incidence or CFTR
allele distribution decreased following implementation of NBS,
although these observations need to be confirmed in larger
studies (51, 52).
IMPLICATIONS OF NBS IN THE ERA OF
MODULATOR THERAPIES
Management of CF has been directed at the downstream
consequences of CFTR dysfunction, incorporating antibiotics,
anti-inflammatory agents, inhaled mucolytics, and airway
clearance techniques. Pancreatic enzyme replacement therapy
and vitamin supplements treat pancreatic insufficiency and
prevent nutritional deficits. These treatments have led to longer
lives, even before widespread implementation of NBS. However,
the emergence of novel small molecule therapeutics that target
the basic defects has raised hope that CF lung disease can
be prevented before it starts. These newer CFTR potentiators
and correctors have mutation-specific effects that can restore
CFTR function. These agents are revolutionizing care and have
reduced respiratory symptoms, exacerbation frequency, and
slowed progression of lung disease in people with CF (12, 13).
When ivacaftor was approved by the US Food and Drug
Administration (FDA) 8 years ago, preceding clinical trials
showed dramatic improvements in sweat chloride values along
with improvements in weight gain, pulmonary exacerbation
rates, and lung function measures in patients with G551D
mutations, a class 3 CFTR gating defect (12, 53). Subsequent
studies revealed improved lung mucociliary clearance that was
sustained 3 months following treatment, which correlated with
forced expiratory volume in 1 s (FEV1) (54). More recently,
several studies then evaluated the effectiveness of ivacaftor in
younger children (55–57). A phase 3, multicenter trial examined
the ivacaftor pharmacokinetics in young children and its effect on
sweat chloride concentrations, growth parameters, and markers
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FIGURE 1 | Early treatment with VX-770 prevents pathological changes in a cystic fibrosis animal model. (A) Effect of the CFTR potentiator VX-770 (ivacaftor) on ion
channel gating of the CFTR G551D mutation. The G551D mutation abolishes ATP-dependent gating, which results in reduced channel open probability, but treatment
with VX-770 alters activity of the mutant CFTR, leading to greater chloride ion and bicarbonate ion secretion, reduced sodium ion absorption, and hydration of
epithelial surfaces. (B) Effect of prenatal and postnatal treatment with VX-770 (ivacaftor) on the airways of young ferrets with G551D mutation. Mucus accumulation,
bacterial infection, and endobronchitis develop early in untreated airways of young kits with G551D mutations, but treated animals avoided bronchial infection and
inflammation until the drug was discontinued. Similar effects were seen in other affected organs, including the pancreas, intestines, and genitourinary tract. Modified
from Ferkol (65).
of exocrine pancreatic function. Growth measures for age
were normal throughout the study, and pancreatic function
biomarkers also improved, suggesting that ivacaftor preserved
exocrine pancreatic function (56). Other studies have shown
beneficial nutritional effects in preschool children (55, 58). These
findings were surprising. In CF, the exocrine pancreas is involved
before birth, with obstruction of small ducts and acini seen as
early as the second trimester (59). Disease progresses after birth,
with pancreatic inflammation, fibrosis, and fatty infiltration, once
thought to occur in early infancy (60).
In secondary analyses of GOAL (G551D Observational
Study), lung clearance indices were significantly improved in
treated children within 1 month of starting treatment and were
maintained 6 months after beginning therapy (61). In fact,
ivacaftor is now approved for use in children with certain
mutations as young as 4 months of age.
Since the development of ivacaftor (Kalydeco (R)), three other
therapies have been approved for use in the United States (62).
Lumacaftor–ivacaftor (Orkambi R©) was initially approved for use
in 2015 for those with homozygous Phe508del mutations and
is now available for use down to 2 years of age. Tezacaftor–
ivacaftor (Symdeko R©) was approved in 2018 and may now be
used for those 6 years or older who have homozygous Phe508del
mutations or Phe508del and a second specific mutation.
Most recently, highly effective triple-drug therapy, elexacaftor–
tezacaftor–ivacaftor (Trikafta R© or Kaftrio R©), was approved by
the FDA and more recently the European Commission for use
in CF patients 12 years or older who have one or two Phe508del
mutations, which accounts for 90% of all affected individuals
(13, 63). This treatment has shown the most promise in altering
the clinical trajectory of those with CF. Trials showed marked
reductions of sweat chloride and improved percent predicted
FEV1 values (13).
Modulator therapy is increasingly used in younger children
and even infants, raising the prospect that CF could be prevented
before it begins (55, 56). However, to be successful, primary
prevention requires early diagnosis and treatment. NBS is an
essential part of the success of early diagnosis and with the advent
of modulator therapy use in younger and younger children,
critically important.
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Given these improvements, although purely speculative,
primary prevention may be achievable. Using genetically
modified ferrets that harbor CFTR G551D mutations,
investigators showed the potential benefits of CFTR modulators
(64). Like other animal models for CF, the newborn ferret
is prone to meconium ileus, with 80% experiencing severe
intestinal obstruction that leads to early death. However, when
pregnant jills were treated with ivacaftor (VX-770) late in
pregnancy, kits homozygous for the G551D mutation had
markedly reduced incidence of neonatal bowel obstruction.
Postnatally, ivacaftor was administered to the kits, and they
maintained pancreatic sufficiency and grew as well as wild-
type littermates. In compound heterozygous (G551D/KO) ferrets,
most remained pancreatic insufficient, but many maintained
normal growth. Similarly, ivacaftor treatment protected the
airways from bacterial infection and inflammation (Figure 1).
Once treatment was discontinued; however, the benefits
disappeared, and CF kits developed characteristic pancreatic and
pulmonary pathology. These findings suggest the importance of
early and sustained modulator treatment in maintaining CFTR
function (65), and these agents are not a cure.
While fertility was not assessed, the vas deferens and
epididymis appeared pathologically normal in male kits
homozygous for the G551D mutation, in contrast to
compound heterozygous (G551D/KO) ferrets. Thus, one
could speculate obstructive azoospermia or congenital
bilateral absence of the vas deferens could be prevented in
certain patients. The pathogenesis of the male genitourinary
defects begins in utero, likely related to accumulation of
obstructing, thickened secretions that leads to degeneration
of the vas deferens. Indeed, male fetuses with CF, between
12- and 18-week gestation, have a normal vas deferens,
demonstrating that the defect occurs later in embryonic
development (66).
It would be premature to consider clinical trials testing
the efficacy of ivacaftor in preventing CF in neonates who
have G551D. First, there would be few eligible subjects.
Few people with CF are homozygous for class 3 CFTR
defects (53). Moreover, treating a fetus by treating an
unaffected pregnant mother would pose ethical issues;
pregnant women and their unborn children are often
excluded from pharmaceutical trials. These therapies
are not without risk, including liver dysfunction and
cataract development, and would likely prohibit use in an
unaffected woman.
That said, we may soon have evidence of whether primary
prevention of CF is feasible. In contrast to their male
counterparts who have obstructive azoospermia, women with
CF are generally fertile, and with improvements in care, a
growing proportion are having children. Many women with
CF are being treated with the newer, highly effective triple
combination therapy, elexacaftor–tezacaftor–ivacaftor (13, 63).
To maintain the mother’s pulmonary and nutritional health, they
often continue treatment throughout pregnancy at many centers.
While partners of pregnant women with CF typically
undergo prenatal testing for CFTR mutations, occasionally
they are missed, and children are born with CF. If their
unborn child has CF and Phe508del mutation(s), he/she
would indirectly be treated with elexacaftor–tezacaftor–
ivacaftor in utero, as these small molecules can cross the
placental barrier, thus leading to several interesting questions.
Would combination therapy in this child prevent progressive
airway disease, maintain pancreatic sufficiency, or preserve
male fertility, paralleling what was described in the ferret
model (65)? How would one assess the latter in young
infants who typically do not have respiratory symptoms
(67), and what would we use to demonstrate a treatment
effect in the lung (67)? For primary prevention strategies
to succeed, sensitive outcome measures are needed to
detect the earliest changes in lung disease in infants and
young children.
Furthermore, would it be unethical to withdraw a drug
that prevented disease once the infant is born, despite lack of
regulatory approval for young infants? If so, in the absence
of clinical trials, how would we determine optimal dosing in
this population?
Finally, would CFTR correction interfere with NBS
of children born to women with CF, resulting in a false-
negative screen? Could CFTR correction attenuate pancreatic
injury and result in a negative IRT level? We may need
to rethink our screening and diagnostic approach for
such children.
While there are many significant gaps in available diagnostics
and treatments between countries (68), we have entered
a new era in CF, full of promise and possibilities. To
achieve this potential, effective screening and diagnostic testing
must be in place. Prenatal and neonatal screening programs
mean that infants can be diagnosed and interventions begun
before they are symptomatic. In some countries, CFTR
genotyping is frequently performed early in life, and mutation-
or class-specific CFTR modulators have already changed
the lives of older infants and children. What was once
unimaginable could become reality—primary prevention of CF
might be achievable.
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